Skip to main content

Pelthos Therapeutics Inc.

corporate_fare Company Profile

Pelthos Therapeutics Inc.

PTHS·NYSE·Life Sciences·CIK 0001919246

Pelthos Therapeutics Inc. is a bio-pharmaceutical company focused on commercializing therapeutic products for patients with unmet treatment burdens. It has three FDA-approved products in its commercial portfolio at various stages of commercialization: ZELSUVMI, XEPI, and XEGLYZE. The July 1, 2025 merger of Channel Therapeutics Corporation and LNHC, Inc. resulted in Pelthos initially having a commercially marketable product, ZELSUVMI for the treatment of molluscum contagiosum, launched in July 2025 shortly after the merger; a manufacturing facility, equipment and know-how to produce the active pharmaceutical ingredient used in ZELSUVMI and the NITRICIL technology platform; and clinical-stage assets that selectively target the sodium ion-channel known as NaV1.7, which has been genetically validated as a pain receptor in human physiology. During the fourth quarter of 2025, the company acquired two additional FDA-approved products to expand its commercial product portfolio. Pelthos was effectively formed on July 1, 2025 through the merger. Channel was originally incorporated in Delaware on March 19, 2021 as Chromocell Therapeutics Corporation, which completed its initial public offering on the NYSE American on February 21, 2024, and was reincorporated in Nevada through a merger on November 18, 2024, concurrent with which it changed its name to Channel Therapeutics Corporation. LNHC was incorporated in Delaware in September 2023 by Ligand Pharmaceuticals, Inc. and was initially formed to facilitate a transaction between Ligand and Novan, Inc.; on September 27, 2023, Ligand acquired certain assets of Novan under Section 363 of the U.S. Bankruptcy Code.

Pelthos Therapeutics Inc. (NYSE:PTHS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 6 items for PTHS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 6 most recent items scored 7 or higher, the top rating is 9/10, with 4 rated 8 or above. Recent SEC coverage for PTHS spans 425, 10-Q, 8-K, SCHEDULE 13D/A.

Recent high-impact activity:

  • Pelthos Q3 Call: Zelsuvmi Revenue $15.2M, Extra $10M Drawn on Horizon Loan
  • Pelthos 10-Q Discloses Unremediated Material Weakness and Restatement Alongside Q3 Results
  • Pelthos Q3: Zelsuvmi Revenue Up 114% to $15.2M, Net Loss Narrows to $7.9M
  • Ligand Commits $33.75M to Pelthos PIPE, Holds 49.9% Voting Blocker Ahead of Castle Creek Merger
  • Pelthos Files Rule 425 Detailing Castle Creek Merger, $57.5M PIPE and Up to $300M Milestones

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$16.8M
Net Income
-$43.32M
Diluted EPS
-$23.04
Op. Cash Flow
-$22.59M
Free Cash Flow
-$22.69M
Gross Profit
$12.81M
Operating Income
-$32.43M
Cash & Equivalents
$17.97M
Total Debt
$31.44M
Debt / Equity
0.81×
Net Margin
-257.9%
Shares Outstanding
3.23M sh
Source: 10-K · filed 2026-03-19 · accession 0001919246-26-000013

Short Interest & Short Volume

2.00 days to cover

FINRA reported short interest of 158,465 shares in PTHS as of the October 30, 2026 settlement, a 11.4% increase from the prior period — about 2.0 days to cover at its recent average daily volume. On November 20, 2026, 67.6% of PTHS volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)158,465 shares as of October 30, 2026
Change vs prior period▲ 11.4%
Days to cover2.00 at avg daily volume of 79,298
Daily short volume (FINRA facilities)67.6% of 35,860 shares on November 20, 2026
5-day average short volume54.2%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with P →
$6.38
52-week range · as of 2026-11-12 $6.38 – $37.4
Market cap
$25.08M
Volume
64K (1.0× avg)
3-mo avg 67K
Live data · 2026-11-22 12:34 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed PTHS - Latest Insights

PTHS
Nov 12, 2026, 4:54 PM EST
Filing Type: 425
Importance Score:
7
Price at Filing: $8.03
Real-time Price: $6.38 info
Change: -$1.65 (-21%) info
Market Cap: $25.078M info
PTHS
Nov 12, 2026, 7:16 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $9.39
Real-time Price: $6.38 info
Change: -$3.01 (-32%) info
Market Cap: $25.078M info
PTHS
Nov 12, 2026, 7:10 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $9.39
Real-time Price: $6.38 info
Change: -$3.01 (-32%) info
Market Cap: $25.078M info
PTHS
Nov 03, 2026, 8:20 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $10.78
Real-time Price: $6.38 info
Change: -$4.40 (-41%) info
Market Cap: $25.078M info
PTHS
Oct 30, 2026, 9:20 AM EDT
Filing Type: 425
Importance Score:
9
Price at Filing: $19.86
Real-time Price: $6.38 info
Change: -$13.48 (-68%) info
Market Cap: $25.078M info
PTHS
Oct 30, 2026, 9:17 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $20.00
Real-time Price: $6.38 info
Change: -$13.62 (-68%) info
Market Cap: $25.078M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets